CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.

Ramachandran, Geetha

CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. [electronic resource] - Antimicrobial agents and chemotherapy Mar 2009 - 863-8 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1098-6596

10.1128/AAC.00899-08 doi


Adult
Alkynes
Anti-HIV Agents--pharmacokinetics
Antibiotics, Antitubercular--therapeutic use
Aryl Hydrocarbon Hydroxylases--genetics
Benzoxazines--pharmacokinetics
Cyclopropanes
Cytochrome P-450 CYP2B6
Drug Therapy, Combination
Female
Geography
HIV Infections--complications
HIV-1--genetics
Humans
India
Male
Middle Aged
Oxidoreductases, N-Demethylating--genetics
Polymorphism, Genetic
Rifampin--adverse effects
Tuberculosis--complications